Monte Rosa Therapeutics (NASDAQ: GLUE) CMO trades 5,407 shares under 10b5-1 plan

Rhea-AI Filing Summary

Monte Rosa Therapeutics Chief Medical Officer Filip Janku exercised stock options and sold shares in a pre-planned transaction. On June 30, he exercised options to acquire 5,407 shares of common stock at $13.41 per share, then sold 5,407 shares at $24.50 per share in an open-market sale pursuant to a Rule 10b5-1 trading plan adopted on March 4, 2026. After these transactions, he directly owned 60,612 shares of common stock, including 620 shares acquired through the company’s 2021 Employee Stock Purchase Program on June 30, 2026.

Insider Trade Summary 10b5-1

Net Seller: 5,407 shares ($132,472)

Net Sell 3 txns

Insider Janku Filip

Role Chief Medical Officer

Sold 5,407 shs ($132K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	5,407	$0.00	--
Exercise	Common Stock	5,407	$13.41	$73K
Sale	Common Stock	5,407	$24.50	$132K

Holdings After Transaction: Stock Option (Right to Buy) — 81,093 shares (Direct, null); Common Stock — 66,019 shares (Direct, null)

Footnotes (1)

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2026. Includes 620 shares acquired under the Issuer's 2021 Employee Stock Purchase Program on June 30, 2026. The shares underlying this option are fully vested and exercisable.

Key Figures

Shares sold: 5,407 shares Sale price: $24.50/share Option exercise size: 5,407 shares +4 more

7 metrics

Shares sold 5,407 shares Open-market sale of common stock on June 30, 2026

Sale price $24.50/share Average price for 5,407 common shares sold

Option exercise size 5,407 shares Common shares acquired via option exercise on June 30, 2026

Option exercise price $13.41/share Exercise price for stock option converted into common shares

Post-transaction holdings 60,612 shares Common stock directly owned after transactions

ESPP shares included 620 shares Acquired under 2021 Employee Stock Purchase Program on June 30, 2026

Rule 10b5-1 adoption date March 4, 2026 Date Janku adopted pre-arranged trading plan

Key Terms

Rule 10b5-1 trading plan, Employee Stock Purchase Program, Stock Option (Right to Buy), open-market sale

4 terms

Rule 10b5-1 trading plan regulatory

"transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2026"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Employee Stock Purchase Program financial

"Includes 620 shares acquired under the Issuer's 2021 Employee Stock Purchase Program on June 30, 2026"

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy) with 5,407 underlying shares of common stock"

open-market sale financial

"Sale in open market or private transaction for 5,407 shares of common stock"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/01/2026 - 04:58 PM Accepted by SEC EDGAR 07/01/2026 - 04:57 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Janku Filip

(Last) (First) (Middle)

MONTE ROSA THERAPEUTICS, INC.

321 HARRISON AVENUE, SUITE 900

(Street)

BOSTON MASSACHUSETTS 02118

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Monte Rosa Therapeutics, Inc. [ GLUE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/30/2026		M(1)		5,407	A	$13.41	66,019(2)	D
Common Stock	06/30/2026		S(1)		5,407	D	$24.5	60,612	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$13.41	06/30/2026		M(1)			5,407	(3)	02/29/2032	Common Stock	5,407	$0	81,093	D

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2026.

2. Includes 620 shares acquired under the Issuer's 2021 Employee Stock Purchase Program on June 30, 2026.

3. The shares underlying this option are fully vested and exercisable.

	/s/ Phil Nickson, Attorney-in-Fact	07/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did GLUE’s Chief Medical Officer report on June 30, 2026?

Filip Janku reported exercising options for 5,407 Monte Rosa Therapeutics shares at $13.41 and selling 5,407 shares at $24.50. These transactions occurred on June 30, 2026 as part of a disclosed trading plan.

How many Monte Rosa Therapeutics (GLUE) shares does Filip Janku hold after this Form 4?

After the reported transactions, Filip Janku directly holds 60,612 shares of Monte Rosa Therapeutics common stock. This total includes 620 shares acquired through the company’s 2021 Employee Stock Purchase Program on June 30, 2026.

Was the GLUE insider sale by Filip Janku made under a Rule 10b5-1 plan?

Yes. The filing states the transactions were effected under a Rule 10b5-1 trading plan adopted on March 4, 2026. Such pre-arranged plans schedule trades in advance, helping separate them from day-to-day market timing decisions.

What price did GLUE’s Chief Medical Officer receive for the shares sold?

Filip Janku sold 5,407 shares of Monte Rosa Therapeutics common stock at an average price of $24.50 per share. The sale followed an option exercise for the same number of shares at an exercise price of $13.41.

What stock options did Filip Janku exercise in this Monte Rosa Therapeutics Form 4?

He exercised a stock option for 5,407 shares of Monte Rosa Therapeutics common stock at an exercise price of $13.41 per share. The filing notes the shares underlying this option were fully vested and exercisable before the transaction.